Co-Founders
Martin Williams
CEO, Co-Founder
Demonstrated leadership building therapeutics companies from the ground floor.
Biotech operator with 20+ yrs experience building therapeutics platforms and a personal commitment as a gout patient -- bringing both strategic vision and lived understanding of the disease to ImmunoFlare's mission.
Prof. Tony Merriman, PhD
CSO, Co-Founder
Professor & Sr. Scientist, and Jane Knight Lowe Chair of Medicine in Rheumatology, UAB. Fellow of the Royal Society of New Zealand. 537+ peer-reviewed publications; 146,000+ citations.
Led the largest gout GWAS ever conducted (Nature Genetics, 2024; 2.6M participants) and the first genome-wide association study for CPPD, identifying ENPP1 as a therapeutic target (Ann Rheum Dis, 2025). PI on multiple NIH grants. Leading author of the definitive review on genetics and genomics of gout.
Advisors
Kiran Pandey, PhD
Advisor -- Proteomics & Business Strategy
Founder and CEO of Proteomics research companies. Ex-McKinsey, GE Healthcare.
Sara Tedeschi, MD, MPH
Advisor -- CPPD & Rheumatology
Head of Crystal-Induced Arthritic Diseases at BWH. Assistant Professor of Medicine, Harvard Medical School. A world-authority on CPPD disease.
Ken Saag, MD, M.Sc.
Advisor -- Gout Therapeutics
Anna Lois Waters Endowed Chair and Director of the Division of Clinical Immunology and Rheumatology. Professor of Medicine, UAB. Major contributor to novel gout therapeutics research. ACR President 2021-2022.
Erik Schwiebert, PhD
Advisor -- Drug Discovery
Director, Biotech Accelerator at Southern Research. Early-stage drug discovery expert with 35 years of experience in academia and translational science.
Join us in redefining crystal disease treatment
We're building partnerships with pharma, biotech, and academic leaders.